Stocktoria
Celldex Therapeutics, Inc. CLDX
Celldex Therapeutics, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $7.0M | $6.9M | $2.4M | $4.7M | $7.4M | $3.6M | $9.5M | $12.7M | $6.8M |
| R&D expense | $245.1M | $163.6M | $118.0M | $82.3M | $53.3M | $42.5M | $42.7M | $66.4M | $96.2M | $102.7M |
| Operating income | -$287.4M | -$195.1M | -$154.5M | -$115.2M | -$71.2M | -$63.4M | -$55.0M | -$156.4M | -$121.5M | -$132.9M |
| Income tax | $0 | $0 | $0 | — | -$227,000 | -$1.2M | — | -$765,000 | -$24.3M | — |
| Net income | -$258.8M | -$157.9M | -$141.4M | — | — | — | — | — | — | — |
| EPS (diluted) | $-3.90 | $-2.45 | $-2.92 | $-2.40 | $-1.64 | $-2.02 | $-3.51 | — | — | — |
| Operating cash flow | -$210.9M | -$157.8M | -$107.3M | -$103.7M | -$60.9M | -$40.4M | -$46.4M | -$75.2M | -$99.9M | -$113.0M |
| Free cash flow | -$213.7M | -$159.7M | -$109.1M | -$105.6M | -$62.2M | -$42.0M | -$47.1M | -$76.0M | -$101.7M | -$115.8M |
| Cash & equivalents | $28.9M | $28.4M | $34.8M | $29.4M | $39.1M | $43.8M | $11.2M | $24.3M | $40.3M | $42.5M |
| Total assets | $583.0M | $792.3M | $465.6M | $352.7M | $444.7M | $235.8M | $122.9M | $155.8M | $315.6M | $383.4M |
| Total liabilities | $55.8M | $45.3M | $36.5M | $26.5M | $25.2M | $26.5M | $28.9M | $31.7M | $79.3M | $117.9M |
| Shareholders' equity | $527.2M | $747.0M | $429.2M | $326.2M | $419.5M | $209.4M | $94.0M | $124.1M | $236.4M | $265.4M |
Growth · year-over-year · Revenue CAGR -15.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -78.0% | +2.0% | +192.0% | -49.3% | -37.3% | +107.6% | -62.5% | -25.2% | +87.8% | +23.8% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.